Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Australian Technology Innovation Fund Limited Prospectus presentation

Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market

Australian Technology

Innovation Fund Limited

Prospectus presentation

Your entry into the lucrative biotech market


The biotech market• Biotechnology is a highly

specialised sector offering excellent investment opportunities to those able to identify projects with global commercialisation potential.

• ATIF identifies and develops biotechnology projects of the highest potential in Australia and offshore. This is your opportunity to own a

share of the lucrative biotech market.


The biotech market• Traditionally, there is a lack of

suitable entities in the biotech market with:– The complex skills required to

target appropriate biotechnology investments

– The ability to cost-effectively manage the risk profile of a specialised biotechnology portfolio.

ATIF has the experienced management and complex skills required for success in this field.


About ATIF• ATIF holds an attractive and

diverse asset base through its interests in three Australian biotechnology companies:– CBio Limited (16.37%)– Psiron Limited (15.93%)– Analytica Limited (14.71%)

ATIF provides assistance to these companies to achieve their commercial objectives.


About ATIF• Directors

– Dr Wolf Hanisch – more than 20 years experience in the biotech industry, including a $45 million IPO for Idec Pharmaceuticals.

– Mr Stephen Jones – corporate recovery and turnaround specialist. Former member of Qld Govt’s Queensland Innovation Council.


About ATIF• Directors cont…

– Dr Michael Monsour – medical practitioner with business interests in QLD medical centres.

ATIF has specialist expertise in biotechnology and capital

financing sectors – a key ATIF advantage.


About ATIF• ATIF’s Board and Management

have high-level scientific and financial experience and are intending ATIF to become Australia’s leading diversified biotechnology company.

• ATIF intends to retain its focus on biotechnology investment, and has formulated the following business plan.


ATIF Business Plan1. Fulfil own working capital

needs from revenues raised through specialist corporate advisory to biotech sector.

2. Effective ongoing management of existing interests.

3. Assisting ATIF investments in achieving product development and funding outcomes.


ATIF Business Plan4. Identifying new investment

opportunities and industry alliances both in Australia and overseas.

5. Integrating acquisitions and developing well-timed “spin off” IPO opportunities.

The ATIF Business Plan gives a clear path for success in the

biotech sector.


ATIF’s Investments

• ATIF has stringent criteria used in selecting current and future investments:– Product-focussed investment

approach– Risk management– Technical competence and

skilled hands-on management– IP protection and product-base

diversification


ATIF’s Investments

• ATIF’s investments are diversified among a variety of complementary biotech areas:– CBio Ltd

• Immune System modulation

– Psiron Ltd• Anti-inflammation, Anti-cancer

– Analytica Ltd • Diagnostics


CBio Ltd• Unlisted Australian Public Company

who owns patent for hormone Early Pregnancy Factor (EPF).

• EPF has patented applications in: – auto-immune disease market (MS

and R. Arthritis) – organ rejection – burns treatment– cancer (diagnosis and therapy)– being prepared for listing “04-05”

on appropriate international exchange.


Psiron Ltd

• Australian Public Company which listed on ASX.

• Operates in biotech/healthcare segment and has investments in– Analytica Ltd.– CBio


Psiron Ltd

• Therapeutics interests are in anti-cancer and anti-inflammation such as:– SPLA2 anti-inflammation

• New generation anti-inflammatory

– Psorafin psoriasis• Psiron owns worldwide rights to

the patented Sorafin compound (treatment for Psoriasis) under and exclusive license.

• Psoriasis is one of the world’s most common skin diseases.


Analytica Ltd

• Australian public company listed on the ASX.

• Diagnostics business with current annual sales revenues of approximately $1.2 million.


The ATIF advantage

Established to take advantage of value-priced investment

opportunities in the biotechnology sector, ATIF

offers industry-specific expertise and an established

and diverse portfolio of biomedical projects and

patents.


The ATIF advantage

• ATIF has the specialist expertise to surmount traditional biotech investment barriers.

• ATIF fills a void in the investment sector.


The ATIF share offer

• 5 million fully-paid shares in ATIF Ltd are on offer at an issue price of $1.00 each.

• Minimum requirement 2000 shares at $1.00 per share, or greater numbers in multiples of 1000 thereafter.

• Applications accepted from 23 October 2002 until 20 December 2002.



• Why Invest in ATIF?– Excellent capital growth

opportunities– Exclusive preferential access

to additional investment opportunities, including underwriting and sub-underwriting agreements, IPOs and other share issues

– The benefit of diversification in the biotechnology sector



By investing in ATIF, shareholders: – Gain ownership of an

excellent capital growth opportunity

– Gain access to key “deal maker” positions resulting from ATIF initiatives


Your opportunity

• This is your opportunity to invest in an attractive and diverse biotechnology asset base, and benefit from:– Diversity through ATIF’s four

investments for price of one– Low entry price for new

investments– Strong Board and Management

team with real experience


Your opportunity

• Further information for your perusal:– Prospectus for Australian

Technology Innovation Fund Limited share offer


Your questions answered

• If you have any questions or would like a copy of the complete prospectus, contact us at ATIF on:Ph. 07 3371 3000Fax. 07 3371 3011Email. [email protected] BX 3104South Brisbane BCQLD 4101 Australia


Your entry into the lucrative

biotech market

Documents

Australian Technology Innovation Fund Limited Your entry into the lucrative biotech market Australian Technology Innovation Fund Limited Prospectus presentation